WoodTrust Financial Corp Purchases 100 Shares of ResMed Inc. (NYSE:RMD)

WoodTrust Financial Corp boosted its holdings in shares of ResMed Inc. (NYSE:RMD) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,620 shares of the medical equipment provider’s stock after acquiring an additional 100 shares during the quarter. WoodTrust Financial Corp’s holdings in ResMed were worth $1,743,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Victory Capital Management Inc. raised its holdings in shares of ResMed by 16.6% during the 4th quarter. Victory Capital Management Inc. now owns 136,029 shares of the medical equipment provider’s stock valued at $31,108,000 after purchasing an additional 19,319 shares in the last quarter. Keybank National Association OH increased its position in ResMed by 18.7% during the fourth quarter. Keybank National Association OH now owns 8,149 shares of the medical equipment provider’s stock worth $1,864,000 after buying an additional 1,283 shares during the last quarter. Exencial Wealth Advisors LLC raised its holdings in ResMed by 26.0% during the fourth quarter. Exencial Wealth Advisors LLC now owns 1,594 shares of the medical equipment provider’s stock valued at $365,000 after buying an additional 329 shares in the last quarter. Commerzbank Aktiengesellschaft FI raised its holdings in ResMed by 17.9% during the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 1,089 shares of the medical equipment provider’s stock valued at $250,000 after buying an additional 165 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of ResMed by 3.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider’s stock worth $218,861,000 after buying an additional 32,973 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ResMed

In other news, insider Kaushik Ghoshal sold 9,113 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $235.40, for a total value of $2,145,200.20. Following the sale, the insider now directly owns 9,725 shares in the company, valued at approximately $2,289,265. This represents a 48.38 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the completion of the transaction, the director now directly owns 77,218 shares of the company’s stock, valued at approximately $18,695,249.98. The trade was a 2.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 19,186 shares of company stock valued at $4,541,226 over the last quarter. 0.71% of the stock is owned by company insiders.

ResMed Trading Down 0.8 %

Shares of RMD opened at $231.31 on Wednesday. The stock’s 50-day moving average price is $237.07 and its 200 day moving average price is $240.02. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $33.97 billion, a price-to-earnings ratio of 27.31, a P/E/G ratio of 1.53 and a beta of 0.70. ResMed Inc. has a 12-month low of $172.19 and a 12-month high of $263.05.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. As a group, research analysts predict that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be given a dividend of $0.53 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.92%. ResMed’s dividend payout ratio (DPR) is currently 25.03%.

Wall Street Analyst Weigh In

RMD has been the topic of a number of recent analyst reports. The Goldman Sachs Group began coverage on ResMed in a research note on Thursday, January 16th. They issued a “buy” rating on the stock. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a research report on Friday, January 31st. KeyCorp upped their price objective on shares of ResMed from $266.00 to $280.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Stifel Nicolaus initiated coverage on shares of ResMed in a report on Friday, December 13th. They issued a “hold” rating and a $250.00 target price on the stock. Finally, UBS Group upgraded shares of ResMed from a “hold” rating to a “strong-buy” rating in a report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $244.73.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.